1887
  1. Home
  2. Eurosurveillance
  3. Volume 22, Issue 9, 02/Mar/2017
  4. Article
Perspective Open Access
Like 0
Download

Abstract

The World Health Organization ‘Global Health Sector Strategy on Viral Hepatitis 2016–2021’ aimed at the elimination of viral hepatitis as a public health threat provides a significant opportunity to increase efforts for tackling the epidemics of hepatitis B and hepatitis C virus infections across Europe. To support the implementation and monitoring of this strategy, core epidemiological and programmatic indicators have been proposed necessitating specific surveys, the systematic collection of programmatic data and the establishment of monitoring across the care pathway. European Union and European Economic Area countries already made progress in recent years implementing primary and secondary prevention measures. Indeed, harm reduction measures among people who inject drugs reach many of those who need them and most countries have a universal hepatitis B vaccination programme with high coverage above 95%. However, while a further scaling up of prevention interventions will impact on incidence of new infections, treating those already infected is necessary to achieve reductions in mortality. The epidemiological, demographic and socio-political situation in Europe is complex, and considerable diversity in the programmatic responses to the hepatitis epidemic exists. Comprehension of such issues alongside collaboration between key organisations and countries will underpin any chance of successfully eliminating hepatitis.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.9.30476
2017-03-02
2018-07-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.9.30476
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/9/eurosurv-22-30476-3.html?itemId=/content/10.2807/1560-7917.ES.2017.22.9.30476&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC. Nov 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/systematic-review-hepatitis-B-C-prevalence.pdf
  2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608.  https://doi.org/10.1016/j.jhep.2012.12.005  PMID: 23419824 
  3. Dultz G, Zeuzem S. Hepatitis C. A European perspective. Gastroenterol Clin North Am. 2015;44(4):807-24.  https://doi.org/10.1016/j.gtc.2015.07.008  PMID: 26600221 
  4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.  https://doi.org/10.1016/S0140-6736(14)61682-2  PMID: 25530442 
  5. World Health Organization (WHO). Combating Hepatitis B and C to reach elimination by 2030. Geneva: WHO; May 2016. Available from: http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf?ua=1
  6. World Health Organization (WHO). Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: WHO; 2016. Available from: http://apps.who.int/iris/bitstream/10665/204790/1/9789241510288_eng.pdf
  7. World Health Organization Regional Office for Europe (WHO/Europe). Action plan for the health sector response to viral hepatitis in the WHO European Region. Copenhagen: WHO/Europe; Sep 2016. Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/315917/66wd10e_HepatitisActionPlan_160555.pdf?ua=1
  8. Duffell EF, Mozalevskis A, Mardh O, Hedrich D. Monitoring the WHO recommended core indicators for viral hepatitis B and C in EU/EEA Member States: supporting the global vision of elimination. Poster session presented at: International Liver Congress of the European Association for the Study of the Liver; Barcelona, Spain. 13-17 Apr 2016.
  9. Duffell EF, van de Laar MJ. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009. Euro Surveill. 2015;20(13):17-24.  https://doi.org/10.2807/1560-7917.ES2015.20.13.21080  PMID: 25860392 
  10. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug-related infectious diseases in Europe: update from the EMCDDA expert network, November 2016. Lisbon: EMCDDA; 2016. Available from: http://www.emcdda.europa.eu/publications/rapid-communications/2016/drug-related-infectious-diseases-in-europe
  11. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hepatitis C among drug users in Europe. Epidemiology, treatment and prevention. Lisbon: EMCDDA; 2016. Available from: http://www.emcdda.europa.eu/system/files/publications/2953/TDXD16002ENN_final_web.pdf
  12. Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46(Suppl 5):S158-64.  https://doi.org/10.1016/j.dld.2014.09.023  PMID: 25453870 
  13. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. . Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7):e103345.  https://doi.org/10.1371/journal.pone.0103345  PMID: 25068274 
  14. European Centre for Disease Prevention and Control (ECDC). Epidemiological assessment of hepatitis B and C prevalence among migrants in the EU/EEA. Stockholm: ECDC; Jul 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/epidemiological-assessment-hepatitis-B-and-C-among-migrants-EU-EEA.pdf
  15. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88(7):558-64. PMID: 22859499 
  16. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2016. Hepatitis B. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/healthtopics/hepatitis_B/Documents/aer2016/AER-hepatitis-B.pdf
  17. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190-200.  https://doi.org/10.1002/hep.27969  PMID: 26146815 
  18. World Health Organization (WHO). Immunization, Vaccines and Biologicals. Data, statistics and graphics. Geneva: WHO; [Accessed 22 Jun 2016]. Available from: http://www.who.int/immunization/monitoring_surveillance/data/en/
  19. European Centre for Disease Prevention and Control (ECDC). Vaccine Schedule. Stockholm: ECDC. [Accessed 24 May 2016]. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
  20. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2016. Hepatitis C. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/healthtopics/hepatitis_C/Documents/aer2016/AER-hepatitis-C.pdf
  21. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011;18(Suppl 1):1-16.  https://doi.org/10.1111/j.1365-2893.2011.01499.x  PMID: 21824223 
  22. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2016: Trends and Developments. Lisbon: EMCDDA; May 2016. Available from: http://www.emcdda.europa.eu/publications/edr/trends-developments/2016
  23. European Union (EU). EU Drugs Strategy (2013 – 20). Off J Eur Union. 2012;C 402/01. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52012XG1229(01)&from=EN
  24. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol. 2013;19(40):6703-9.  https://doi.org/10.3748/wjg.v19.i40.6703  PMID: 24187444 
  25. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10(1):7.  https://doi.org/10.1186/1477-7517-10-7  PMID: 23651646 
  26. Seedat F, Hargreaves S, Friedland JS. Engaging new migrants in infectious disease screening: a qualitative semi-structured interview study of UK migrant community health-care leads. PLoS One. 2014;9(10):e108261.  https://doi.org/10.1371/journal.pone.0108261  PMID: 25330079 
  27. European Commission. Crisis Preparedness and Response. Joint Procurement of medical countermeasures. Brussels: European Commission. [Accessed 14 Jun 2016]. Available from: http://ec.europa.eu/health/preparedness_response/joint_procurement/index_en.htm
  28. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO; Mar 2015. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1
  29. World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version. Geneva: WHO; Apr 2016. http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1.
  30. World Health Organization (WHO). Manual for the development and assessment of national viral hepatitis plans: a provisional document. Geneva: WHO; Sep 2015. Available from: http://apps.who.int/iris/bitstream/10665/183726/1/9789241509350_eng.pdf
  31. Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16(12):1409-22. PMID: 27615026 
Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Erika+F+Duffell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duffell Erika F</a>, <a href="/search?value1=Dagmar+Hedrich&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hedrich Dagmar</a>, <a href="/search?value1=Otilia+Mardh&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mardh Otilia</a>, <a href="/search?value1=Antons+Mozalevskis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mozalevskis Antons</a></span>. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions. <a href="/content/ecdc">Euro Surveill.</a> 2017;22(9):pii=30476. <a href="https://doi.org/10.2807/1560-7917.ES.2017.22.9.30476" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2017.22.9.30476</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 23 Jun 2016;&nbsp;&nbsp; <span class="generated">Accepted</span>: 09 Nov 2016 </span> </p>
/content/10.2807/1560-7917.ES.2017.22.9.30476
/content/10.2807/1560-7917.ES.2017.22.9.30476
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error